Previous 10 | Next 10 |
AFM24 induces strong tumor cell killing independent of KRAS mutations AFM24, in combination with adoptive NK cells, leads to dose-dependent tumor regression Heidelberg, Germany, April 12, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology compa...
Could These Biotech Stocks Be The Best Stocks To Invest In Right Now? You can’t deny that biotech stocks have and continue to receive a whole lot of attention from investors now. Accordingly, this is because of the current pandemic where biotech companies are continuously...
Shares of drugmaker Affimed (NASDAQ: AFMD) are up 19% at 2:06 p.m. EDT after the company disclosed positive data from an early-stage clinical trial of its innate cell engager AFM13 in patients with Hodgkin's lymphoma. The data release only included results from the first four pa...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Affimed N.V Announces Positive Initial Clinical Data ” Affimed N.V. (NASDAQ: AFMD) surged over 30% in premarket trading after the co...
Gainers: Celcuity (CELC) +43%.NCS Multistage (NCSM) +39%.MEDIROM Healthcare Technologies (MRM) +31%.Natuzzi (NTZ) +24%.Affimed (AFMD) +23%.Tenax Therapeutics (TENX) +23%.Brooklyn ImmunoTherapeutics (BTX) +20%.GT Biopharma (GTBP) +16%.Sohu.com (SOHU) +15%.fuboTV (...
Shares of Affimed N.V. (NASDAQ:AFMD) traded today at $10.69, eclipsing its 52-week high. Approximately 7.2 million shares have changed hands today, as compared to an average 30-day volume of 2.1 million shares. Affimed N.V. share prices have moved between a 52-week high of $10.69 and a 5...
Gainers: Celcuity (CELC) +56%, GeoVax Labs (GOVX) +36%, Affimed (AFMD) +24%, Tenax Therapeutics (TENX) +22%, Genetic Technologies (GENE) +13%.Losers: Novo Integrated Sciences (NVOS) -24%, Provention Bio (PRVB) -21%, Virpax ...
Celcuity (CELC) +55% on licensing agreement up to $340M for breast cancer treatment gedatolisib.Affimed N.V. (AFMD) +29% on positive data from NK cells + AFM13 in solid tumors.Greenwich LifeSciences (GLSI) +29% on robust immune response Phase IIb data in breast cancer.Gulf Reso...
Affimed (AFMD) announces positive initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed’s innate cell engager AFM13 (CD16A/CD30) in adult patients with recurrent/refractory CD30-positive lymphomas...
All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100% There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-v...
News, Short Squeeze, Breakout and More Instantly...
2024-07-07 08:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 17:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...